CV Therapeutics Submits Supplemental New Drug Application For Ranexa(R) (ranolazine Extended-release Tablets)

CV Therapeutics, Inc. (Nasdaq: CVTX) announced that the Company has submitted a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking an expansion to the approved product labeling for Ranexa(R) (ranolazine extended-release tablets). [click link for full article]

More: continued here

Filed under: Cardiovascular on September 28th, 2007